2 results
Not approvedWill not start
Primary: To evaluate local tumour control by using HIFU technology.Secondary: To evaluate treatment toxicity, disease progression and QoL.
Approved WMOCompleted
To determine the feasibility, toxicity and safety of anti-CEA x anti hapten bispecific antibodies (TF2) and Lu-177-labelled di-HSG-DOTA peptide (IMP-288) in patients with advanced colorectal carcinoma.